Mucosal immunization with attenuated Aalmonella enterica serovar typhi expressing protective antigen of anthrax toxin (PA83) primes monkeys for accelerated serum antibody responses to parenteral PA83 vaccine

Journal of Infectious Diseases

Volumn 199, Issue 3, 2009, Pages 326-335

  Galen, James E ^a,b   Chinchilla, Magaly ^a,b   Pasetti, Marcela F ^a,b   Jin, Yuan Wang ^a,b   Zhao, Licheng ^a,b   Arciniega Martinez, Ivonne ^a,b   Silverman, David J ^b   Levine, Myron M ^a,b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM POTASSIUM SULFATE; ANTHRAX TOXIN; ANTHRAX VACCINE; ANTIBODY; ANTIGEN; BACTERIAL PROTEIN; BACTERIAL VACCINE; CLYA PROTEIN; CVD 908 HTRA; SUBUNIT VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNIZATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHESUS MONKEY; SALMONELLA ENTERICA; SALMONELLA TYPHI;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTHRAX VACCINES; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; DRUG ADMINISTRATION ROUTES; FEMALE; GENETIC ENGINEERING; IMMUNIZATION, SECONDARY; IMMUNOGLOBULIN G; MACACA FASCICULARIS; MACACA MULATTA; MALE; NASAL MUCOSA; RANDOM ALLOCATION; SALMONELLA TYPHI; VACCINES, ATTENUATED;

EID: 58849119173     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/596066     Document Type: Article

References (35)

1. Jernigan DB, Raghunathan PL, Bell BP, et al. Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis 2002; 8:1019-28.
2. Cieslak TJ, Kortepeter MG, Eitzen EM Jr. Vaccines against agents of bioterrorism. In: Levine MM, Kaper JB, Rappuoli R, Liu MA, Good MF, eds. New generation vaccines. 3rd ed. New York: Marcel Dekker, 2004:1067-79.
3. Hanson JF, Taft SC, Weiss AA. Neutralizing antibodies and persistence of immunity following anthrax vaccination. Clin Vaccine Immunol 2006; 13:208-13.
4. Vitale L, Blanset D, Lowy I, et al. Prophylaxis and therapy of inhalational anthrax by a novel monoclonal antibody to protective antigen that mimics vaccine-induced immunity. Infect Immun 2006; 74:5840-7.
5. Phipps AJ, Premanandan C, Barnewall RE, Lairmore MD. Rabbit and nonhuman primate models of toxin-targeting human anthrax vaccines. Microbiol Mol Biol Rev 2004; 68:617-29.
6. Little SF, Ivins BE, Fellows PF, Pitt ML, Norris SL, Andrews GP. Defining a serological correlate of protection in rabbits for a recombinant anthrax vaccine. Vaccine 2004; 22:422-30.
7. Pitt ML, Little S, Ivins BE, et al. In vitro correlate of immunity in an animal model of inhalational anthrax. J Appl Microbiol 1999; 87:304.
8. Williamson ED, Hodgson I, Walker NJ, et al. Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax. Infect Immun 2005; 73:5978-87.
9. Brey RN. Molecular basis for improved anthrax vaccines. Adv Drug Deliv Rev 2005; 57:1266-92.
10. Grabenstein JD. Countering anthrax: vaccines and immunoglobulins. Clin Infect Dis 2008; 46:129-36.
11. Joellenbeck LM, Zwanziger LL, Durch JS, Strom BL. The anthrax vaccine: is it safe? Does it work? Washington, DC: National Academy Press, 2002.
12. Payne DC, Rose CE Jr, Aranas A, et al. Assessment of anthrax vaccination data in the Defense Medical Surveillance System, 1998-2004. Pharmacoepidemiol Drug Saf 2007; 16:605-11.
13. Martin SW, Tierney BC, Aranas A, et al. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. Pharmacoepidemiol Drug Saf 2005; 14:393-401.
14. Fowler GL, Baggs JM, Weintraub ES, Martin SW, McNeil MM, Gust DA. Factors influencing laboratory workers' decisions to accept or decline anthrax vaccine adsorbed (AVA): results of a decision-making study in CDC's anthrax vaccination program. Pharmacoepidemiol Drug Saf 2006; 15:880-8.
15. Nass M. The Anthrax Vaccine Program: an analysis of the CDC's recommendations for vaccine use. Am J Public Health 2002; 92:715-21.
16. US General Accounting Office. Anthrax vaccine. GAO's survey of guard and reserve pilots and aircrew. Report GAO-02-445. Washington, DC: US General Accounting Office, 2002.
17. Little SF, Ivins BE, Webster WM, Norris SL, Andrews GP. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine. Vaccine 2007; 25:2771-7.
18. Campbell JD, Clement KH, Wasserman SS, Donegan S, Chrisley L, Kotloff KL. Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults. Hum Vaccin 2007; 3:205-11.
19. Gorse GJ, Keitel W, Keyserling H, et al. Immunogenicity and tolerance of ascending doses of a recombinant protective antigen (rPA102) anthrax vaccine: a randomized, double-blinded, controlled, multicenter trial. Vaccine 2006; 24:5950-9.
20. Sambrook J, MacCallum P, Russell D. Molecular cloning: a laboratory manual. 3rd ed. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2001.
21. Tacket CO, Sztein MB, Wasserman SS, et al. Phase 2 clinical trial of attenuated Salmonella enterica serovar Typhi oral live vector vaccine CVD 908-htrA in U.S. volunteers. Infect Immun 2000; 68:1196-201.
22. Galen JE, Chinchilla M, Zhao L, et al. Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live vector vaccine strain CVD 908-htrA. Infect Immun 2004; 72:7096-106.
23. Quinn CP, Dull PM, Semenova V, et al. Immune responses to Bacillus anthracis protective antigen in patients with bioterrorism-related cutaneous or inhalation anthrax. J Infect Dis 2004; 190:1228-36.
24. Li H, Soroka SD, Taylor TH Jr, et al. Standardized, mathematical model-based and validated in vitro analysis of anthrax lethal toxin neutralization. J Immunol Methods 2008; 333:89-106.
25. Crockett M, Keystone J. "I hate needles" and other factors impacting on travel vaccine uptake. J Travel Med 2005; 12(Suppl 1):S41-6.
26. Nir Y, Paz A, Sabo E, Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg 2003; 68:341-4.
27. Tacket CO, Galen J, Sztein MB, et al. Safety and immune responses to attenuated Salmonella enterica serovar Typhi oral live vector vaccines expressing tetanus toxin fragment C. Clin Immunol 2000; 97:146-53.
28. Levine MM, Taylor DN, Ferreccio C. Typhoid vaccines come of age. Pediatr Infect Dis J 1989; 8:374-81.
29. Kang HY, Curtiss R III. Immune responses dependent on antigen location in recombinant attenuated Salmonella typhimurium vaccines following oral immunization. FEMS Immunol Med Microbiol 2003; 37:99-104.
30. Hess J, Gentschev I, Miko D, et al. Superior efficacy of secreted over somatic antigen display in recombinant Salmonella vaccine induced protection against listeriosis. Proc Natl Acad Sci USA 1996; 93:1458-63.
31. Galen JE, Levine MM. Can a 'flawless' live vector vaccine strain be engineered? Trends Microbiol 2001; 9:372-6.
32. Stokes MG, Titball RW, Neeson BN, et al. Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis. Infect Immun 2007; 75:1827-34.
33. Pittman PR, Norris SL, Barrera Oro JG, Bedwell D, Cannon TL, McKee KT Jr. Patterns of antibody response in humans to the anthrax vaccine adsorbed (AVA) primary (six-dose) series. Vaccine 2006; 24:3654-60.
34. Calvas P, Apoil P, Fortenfant F, et al. Characterization of the three immunoglobulin G subclasses of macaques. Scand J Immunol 1999; 49:595-610.
35. Semenova VA, Schmidt DS, Taylor TH Jr, et al. Analysis of antiprotective antigen IgG subclass distribution in recipients of anthrax vaccine adsorbed (AVA) and patients with cutaneous and inhalation anthrax. Vaccine 2007; 25:1780-8.